MA27852A1 - Derives de 1-(alkylaminoalkyl-pyrolidin-/piperidinyl)-2,2-diphenylacetamide utilises comme antagonistes du recepteur muscarinique - Google Patents

Derives de 1-(alkylaminoalkyl-pyrolidin-/piperidinyl)-2,2-diphenylacetamide utilises comme antagonistes du recepteur muscarinique

Info

Publication number
MA27852A1
MA27852A1 MA28650A MA28650A MA27852A1 MA 27852 A1 MA27852 A1 MA 27852A1 MA 28650 A MA28650 A MA 28650A MA 28650 A MA28650 A MA 28650A MA 27852 A1 MA27852 A1 MA 27852A1
Authority
MA
Morocco
Prior art keywords
compounds
muscarinic receptor
pyrolidin
alkylaminoalkyl
piperidinyl
Prior art date
Application number
MA28650A
Other languages
English (en)
Inventor
Mathai Mammen
Adam Hughes
Yu-Hua Ji
Li Li
Weijiang Zhang
Original Assignee
Theravance Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Inc filed Critical Theravance Inc
Publication of MA27852A1 publication Critical patent/MA27852A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrrole Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des composés représentés par la formule générale (I) dans laquelle R1-R5 et a-e sont des éléments définis dans la description ; ou des sels ou des solvates ou encore des stéréo-isomères de qualité pharmaceutique de ces composés. L'invention concerne également des compositions pharmaceutiques contenant ces composés ; des procédés et des produits intermédiaires destinés à la préparation de ces composés ; ainsi que des méthodes destinées au traitement d'états pathologiques induits par les récepteurs muscariniques, utilisant ces composés.
MA28650A 2003-06-13 2005-12-09 Derives de 1-(alkylaminoalkyl-pyrolidin-/piperidinyl)-2,2-diphenylacetamide utilises comme antagonistes du recepteur muscarinique MA27852A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US47845603P 2003-06-13 2003-06-13

Publications (1)

Publication Number Publication Date
MA27852A1 true MA27852A1 (fr) 2006-04-03

Family

ID=33563773

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28650A MA27852A1 (fr) 2003-06-13 2005-12-09 Derives de 1-(alkylaminoalkyl-pyrolidin-/piperidinyl)-2,2-diphenylacetamide utilises comme antagonistes du recepteur muscarinique

Country Status (22)

Country Link
US (5) US7183292B2 (fr)
EP (1) EP1633707A1 (fr)
JP (1) JP2007507496A (fr)
KR (1) KR20060017541A (fr)
CN (2) CN100406435C (fr)
AR (1) AR044676A1 (fr)
AU (1) AU2004253869B2 (fr)
BR (1) BRPI0411358A (fr)
CA (1) CA2525801A1 (fr)
CL (1) CL2004001431A1 (fr)
CO (1) CO5650231A2 (fr)
IS (1) IS8155A (fr)
MA (1) MA27852A1 (fr)
MX (1) MXPA05013256A (fr)
MY (1) MY139290A (fr)
NO (1) NO20060191L (fr)
NZ (1) NZ543805A (fr)
PE (1) PE20050282A1 (fr)
RU (1) RU2337095C2 (fr)
TW (1) TW200510298A (fr)
WO (1) WO2005003090A1 (fr)
ZA (1) ZA200509942B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200800953A (en) * 2002-10-30 2008-01-01 Theravance Inc Intermediates for preparing substituted 4-amino-1-(pyridylmethyl) piperidine
PE20040950A1 (es) * 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
TW200510298A (en) * 2003-06-13 2005-03-16 Theravance Inc Substituted pyrrolidine and related compounds
JP2007524641A (ja) * 2003-07-11 2007-08-30 セラヴァンス， インコーポレーテッド 置換４−アミノ−１−ベンジルピペリジン化合物
EP1723142A1 (fr) * 2004-03-11 2006-11-22 Theravance, Inc. Composes de diphenylmethyle, antagonistes du recepteur muscarinique
EP1725525A1 (fr) * 2004-03-11 2006-11-29 Theravance, Inc. Composes biphenyle convenant en tant qu'antagonistes du recepteur muscarinique
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
TW200540154A (en) * 2004-06-10 2005-12-16 Theravance Inc Crystalline form of a substituted pyrrolidine compound
GB0516313D0 (en) 2005-08-08 2005-09-14 Argenta Discovery Ltd Azole derivatives and their uses
KR101495708B1 (ko) * 2007-02-23 2015-02-25 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 무스카린 수용체 안타고니스트로 유용한 4차 암모늄 디페닐메틸 화합물

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3192206A (en) 1961-12-04 1965-06-29 Robins Co Inc A H 4-(omega-aminoalkyl)-3, 3-disubstitutedn-hydrocarbon-2-pyrrolidinones and corresponding-2-thionpyrrolidinones
US3192210A (en) 1961-12-04 1965-06-29 Robins Co Inc A H 4-(omega-substituted alkyl)-3, 3-disubstituted-1-substituted-2-pyrrolidinones and 4-(omega-substituted alkyl)-3, 3-disubstituted-1-substituted-2-thionpyrrolidinones
US3192221A (en) 1961-12-04 1965-06-29 Robins Co Inc A H 4-(omega-substituted alkyl)-3, 3-disubstituted-1-substituted-2-pyrrolidinones and 4-(omega-substituted alkyl)-3, 3-disubstituted-1-substituted-2-thionpyrrolidinones and production thereof
US3247222A (en) 1962-12-26 1966-04-19 Robins Co Inc A H Alpha (nu-hydrocarbonpyrrolidyl-3-) alpha, alpha carbocyclic arylacetamides
US3732247A (en) 1970-08-14 1973-05-08 Robins Co Inc A H 3-di-substituted methylene pyrrolidines wherein the 1-or n-lower-alkyl substituent contains at least two carbon atoms
US3984557A (en) 1974-12-26 1976-10-05 A. H. Robins Company, Incorporated Antiarrhythmia compositions and methods
US4002766A (en) 1974-12-26 1977-01-11 A. H. Robins Company, Incorporated Antiarrhythmia methods
BR8007911A (pt) 1979-12-06 1981-06-16 Glaxo Group Ltd Inalador aperfeicoado
JPS57175165A (en) * 1981-04-21 1982-10-28 Tokyo Tanabe Co Ltd Novel 1,4-dihydropyridine-3,5-dicarboxylic diester derivative and its salt
EP0069715B1 (fr) 1981-07-08 1986-11-05 Aktiebolaget Draco Inhalateur de poudre
IL76583A (en) * 1984-10-19 1988-08-31 Robins Co Inc A H 1-(aminoalkyl)-alpha'alpha-diaryl pyrrolidinyl,piperidino and homopiperidino acetamides and acetonitriles and pharmaceutical compositions containing them
US4594343A (en) 1984-10-19 1986-06-10 Shanklin Jr James R 1-[(aminoalkyl and aminoalkylamino)carbonyl and thiocarbonyl]-α,α-diarylpyrrolidine, piperidine and homopiperidineacetamides and acetonitriles
AU591152B2 (en) 1985-07-30 1989-11-30 Glaxo Group Limited Devices for administering medicaments to patients
US4810713A (en) 1985-12-20 1989-03-07 A. H. Robins Company, Incorporated Arylalkyl-heterocyclic amines, n-substituted by aryloxyalkyl groups used in a method for allergy treatment
EP0228893A3 (fr) 1985-12-20 1990-01-03 A.H. ROBINS COMPANY, INCORPORATED (a Delaware corporation) Amines arylalkyl-hétérocycliques N-substitués par un groupe aryloxyalkyl dans le traitement des allergies
IN163948B (fr) * 1986-01-17 1988-12-10 Robins Co Inc A H
US5932594A (en) 1988-11-01 1999-08-03 Pfizer, Inc. Muscarinic receptor antagonists
US5225183A (en) 1988-12-06 1993-07-06 Riker Laboratories, Inc. Medicinal aerosol formulations
US5233053A (en) 1989-03-17 1993-08-03 Pfizer Inc. Pyrrolidine derivatives
GB8906166D0 (en) * 1989-03-17 1989-05-04 Pfizer Ltd Therapeutic agents
US5070087A (en) 1989-05-08 1991-12-03 A. H. Robins Company, Incorporated Aryl(alkyland alkylene)-N-((phenoxy and phenylthio)alkyl) aminoheterocyclics as cardiovascular, anthihistaminic, antisecretory and antiallergy agents
GB8928042D0 (en) 1989-12-12 1990-02-14 Pfizer Ltd Muscarinic receptor antagonists
GB9000301D0 (en) 1990-01-06 1990-03-07 Pfizer Ltd Piperidine & pyrrolidine derivatives
US5607950A (en) 1990-01-06 1997-03-04 Pfizer Inc. Muscarinic receptor antagonists
US5486527A (en) 1990-01-06 1996-01-23 Pfizer Inc. Anticholinergic agents
SK280968B6 (sk) 1990-03-02 2000-10-09 Glaxo Group Limited Balenie medikamentu na použite v inhalačnom prístroji
JP2997705B2 (ja) * 1990-08-01 2000-01-11 株式会社ネオス 静電荷像現像用トナー
JP3005024B2 (ja) * 1990-08-03 2000-01-31 株式会社ネオス 摩擦帯電付与部材
WO1992022286A1 (fr) 1991-06-12 1992-12-23 Minnesota Mining And Manufacturing Company Formulations pour aerosol en suspension comprenant du sulfate d'albuterol
US5337740A (en) 1991-08-01 1994-08-16 New England Pharmaceuticals, Inc. Inhalation devices
DK0717987T3 (da) 1991-12-18 2001-11-12 Minnesota Mining & Mfg Suspension-aerosol-formuleringer
SE9202218D0 (sv) * 1992-07-22 1992-07-22 Kabi Pharmacia Ab Pharmacologically active alfa-(tertiary-aminomethyl)-benzenemethanol derivatives, pharmaceutical composition containing them, therapeutical use thereof and processes for their preparation
US5239993A (en) 1992-08-26 1993-08-31 Glaxo Inc. Dosage inhalator providing optimized compound inhalation trajectory
US5415162A (en) 1994-01-18 1995-05-16 Glaxo Inc. Multi-dose dry powder inhalation device
KR19990008109A (ko) 1995-04-28 1999-01-25 나가사까 겐지로 1,4-이치환 피페리딘 유도체
JPH0971048A (ja) * 1995-09-06 1997-03-18 Fuji Photo Film Co Ltd 感熱記録材料
ATE205490T1 (de) 1995-10-13 2001-09-15 Banyu Pharma Co Ltd Substituierte heteroaromatische derivate
WO1998054167A1 (fr) 1997-05-28 1998-12-03 Mitsubishi-Tokyo Pharmaceuticals, Inc. Composes d'indole
AU8357198A (en) 1997-07-24 1999-02-16 Mitsubishi-Tokyo Pharmaceuticals, Inc. Aminocycloalkane compounds
JPH11100366A (ja) 1997-09-29 1999-04-13 Kyorin Pharmaceut Co Ltd 新規ｎ−置換環状アミン誘導体及びその製造法
AU763638B2 (en) 1998-06-08 2003-07-31 Theravance Biopharma R&D Ip, Llc Muscarinic receptor antagonists
US6409330B1 (en) 1998-07-14 2002-06-25 Seiko Epson Corporation Sublimation transfer ink jet recording method and ink composition for use therein
US6693202B1 (en) 1999-02-16 2004-02-17 Theravance, Inc. Muscarinic receptor antagonists
DE19921693A1 (de) 1999-05-12 2000-11-16 Boehringer Ingelheim Pharma Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika
US6403810B2 (en) * 2000-07-10 2002-06-11 Hoffmann-La Roche Inc. Thiophene derivatives
US20030018019A1 (en) 2001-06-23 2003-01-23 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics
TW200800953A (en) * 2002-10-30 2008-01-01 Theravance Inc Intermediates for preparing substituted 4-amino-1-(pyridylmethyl) piperidine
JP4767842B2 (ja) 2003-04-01 2011-09-07 セラヴァンス， インコーポレーテッド β２アドレナリン作用性レセプターアゴニスト活性およびムスカリン性レセプターアンタゴニスト活性を有するジアリールメチル化合物および関連化合物
TW200510298A (en) 2003-06-13 2005-03-16 Theravance Inc Substituted pyrrolidine and related compounds
JP2007524641A (ja) * 2003-07-11 2007-08-30 セラヴァンス， インコーポレーテッド 置換４−アミノ−１−ベンジルピペリジン化合物
PE20050973A1 (es) * 2003-10-29 2005-11-19 Theravance Inc Sales de acido naftalen-1,5-disulfonico de un compuesto de 4-amino-1-(piridilmetil)piperidina como antagonistas de receptores muscarinicos
EP1723142A1 (fr) 2004-03-11 2006-11-22 Theravance, Inc. Composes de diphenylmethyle, antagonistes du recepteur muscarinique
EP1725525A1 (fr) 2004-03-11 2006-11-29 Theravance, Inc. Composes biphenyle convenant en tant qu'antagonistes du recepteur muscarinique
TW200540154A (en) 2004-06-10 2005-12-16 Theravance Inc Crystalline form of a substituted pyrrolidine compound

Also Published As

Publication number Publication date
US20080161577A1 (en) 2008-07-03
CA2525801A1 (fr) 2005-01-13
JP2007507496A (ja) 2007-03-29
US7615566B2 (en) 2009-11-10
CN101108809B (zh) 2010-07-14
ZA200509942B (en) 2006-12-27
TW200510298A (en) 2005-03-16
US7638639B2 (en) 2009-12-29
MXPA05013256A (es) 2006-03-09
MY139290A (en) 2009-09-30
US20040254219A1 (en) 2004-12-16
US7183292B2 (en) 2007-02-27
US7351718B2 (en) 2008-04-01
CN1805927A (zh) 2006-07-19
AU2004253869A1 (en) 2005-01-13
WO2005003090A1 (fr) 2005-01-13
AR044676A1 (es) 2005-09-21
CL2004001431A1 (es) 2005-03-18
CN100406435C (zh) 2008-07-30
NO20060191L (no) 2006-03-10
PE20050282A1 (es) 2005-04-29
RU2337095C2 (ru) 2008-10-27
KR20060017541A (ko) 2006-02-23
NZ543805A (en) 2009-06-26
US20080146649A1 (en) 2008-06-19
AU2004253869B2 (en) 2010-02-18
US20070078163A1 (en) 2007-04-05
US7351717B2 (en) 2008-04-01
RU2006101151A (ru) 2006-06-27
CN101108809A (zh) 2008-01-23
IS8155A (is) 2005-11-28
CO5650231A2 (es) 2006-06-30
EP1633707A1 (fr) 2006-03-15
BRPI0411358A (pt) 2006-07-25
US20070135482A1 (en) 2007-06-14

Similar Documents

Publication Publication Date Title
MA28747B1 (fr) Dérivés de pyridine
MA27774A1 (fr) Inhibiteurs de phosphatidylinositol 3-kinase
MA31766B1 (fr) Composés organiques
MA29926B1 (fr) Derives de pyrazine
MA30696B1 (fr) Derives de l'acide (3-amino-1,2,3,4-tetrahydro-9h-carbazol-9-yl)-acetique
TNSN04156A1 (fr) Pyridinones substituees servant de modulateurs de la map-kinase p38
MA30089B1 (fr) (arylsulfonyl)-pyrasolopiperidines
TNSN05250A1 (fr) Pyrimidinones substituees
MA27775A1 (fr) Composes organiques
MA30411B1 (fr) Derives de triazolopyrazine utiles comme agent anticancereux
MA31521B1 (fr) Dérivés de 2,3-dihydrobenzo[1,4] dioxin-2-ylméthyle utilisés en tant qu'antagonistes des alpha2c pour traiter des maladies des systèmes nerveux périphérique et central
MA29772B1 (fr) Benzimidazoles substitues et procedes de preparation
MA27568A1 (fr) Derives de pyrrolopyrimidine
TNSN07248A1 (fr) Derive de pyrrolidyle de composes heteroaromatiques servant d'inhibiteurs de phosphodiesterases
MA29170B1 (fr) Derives puriniques agissant comme des agonistes du recepteur a2a
MA31373B1 (fr) Composes amino-heterocycliques
MA27883A1 (fr) Derives de pyrido [2,1-a] isoquinoline utilises comme inhibiteurs de dpp-iv
TN2009000450A1 (fr) Derives de pyridine
MA29140B1 (fr) Dérivés de quinoléine hétéroaromatiques et leur utilisation comme inhibiteurs de PDE10
MA30911B1 (fr) Nouveaux derives de sulfonamide en tant qu'antagonistes de bradykinine
MA31952B1 (fr) Pyrrolopyrimidines et pyrrolopyridines
MA27347A1 (fr) Inhibiteurs de protease du vih, compositions les contenant, leurs utilisations pharmaceutiques et matieres pour leur synthese
MA30333B1 (fr) Aminotetrahydropyranes utiles en tant qu'inhibiteurs de la dipeptidyle peptidase-iv pour le traitement ou la prevention du diabete.
TNSN07349A1 (fr) Derives de n-(n-sulfonylaminomethyl) cyclopropanecarboxamide utiles pour le traitement de la douleur
MA27389A1 (fr) Derives de benzimidazole nouveaux utiles comme agents antiproliferatifs.